ArticleGut and liver2018
Quality Metrics of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program in Korea.
Article in Gut and liver, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A Validation Study of Methylated Syndecan-2 in Stool DNA for the Detection of Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Diagnostic Yield of Fecal Immunochemical Test for Advanced Colorectal Neoplasms in Adults Under 50: A Single-Center Cohort in Taiwan.Journal of clinical medicine · 2026Article
- Cost-Effectiveness of Colonoscopy for Screening: What Matters Most?Gut and liver · 2026Article
- [Achievements and Future Directions of the National Colorectal Cancer Screening Program in Korea].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Article
- Diagnostic performance of colonoscopy after positive FIT in National Cancer Screening Program.Medicine · 2026Article
- Stool DNA-based SDC2 Methylation Test for the Screening of Colorectal Neoplasia in an Asymptomatic, Average-Risk Population.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Article
- Fecal Immunochemical Testing for Colorectal Cancer Prevention in Two Public Hospitals.Journal of gastrointestinal cancer · 2025Article
- Epidemiology, Risk Factors, and Prevention of Colorectal Cancer-An English Version.Journal of the anus, rectum and colon · 2022Review
- National Colorectal Cancer Screening Program in Lithuania: Description of the 5-Year Performance on Population Level.Cancers · 2021Article
- Quality Indicators and Outcome Measures of Endoscopy in the National Cancer Screening Program.Yonsei medical journal · 2019Article
- Detection of Colorectal Neoplasia in a Cohort Before and After the Change of Fecal Occult Blood Test in a French Colorectal Cancer Screening Program.The American journal of gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsKnowledge regarding the quality metrics of fecal immunochemical test (FIT)-based colorectal cancer screening programs is limited. The aim of this study was to investigate the performance and quality metrics of a FIT-based screening program.
methodsIn our screening program, asymptomatic subjects aged ≥50 years underwent an annual FIT, and subjects with positive FIT results underwent a subsequent colonoscopy. The performance of the FIT and colonoscopy was analyzed in individuals with a positive FIT who completed the program between 2009 and 2015 at a university hospital.
resultsAmong the 51,439 screened participants, 75.1% completed the FIT. The positive rate was 1.1%, and the colonoscopy completion rate in these patients was 68.6%. The positive predictive values of cancer and advanced neoplasia were 5.5% and 19.1%, respectively. The adenoma detection rate in the patients who underwent colonoscopy after a positive FIT was 48.2% (60.0% for men and 33.6% for women). The group with the highest tertile quantitative FIT level showed a significantly higher detection rate of advanced neoplasia than the group with the lowest tertile (odds ratio, 2.6; 95% confidence interval, 1.4 to 5.1; p＜0.001).
conclusionsThe quality metrics used in the United States and Europe may be directly introduced to other countries, including Korea. However, the optimal quality metrics should be established in each country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.